Carson City, Nevada--(Newsfile Corp. - December 12, 2018) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices.
Upon receiving its Certificate of Conformity, qualifying the eBalance devices as Class A (professional use) and Class B (in home use) as well as its CSA, CE and UL Certifications for meeting electrical safety and emission standards from LabTest Certification Inc., the Company collaborated with its production facility operated by NDS Electronic Solutions Inc. ("NDS") in order to manufacture the eBalance devices. NDS is a British Columbia owned and operated business. The devices are manufactured in accordance with the design specifications and stringent standards imposed by the Company.
In addition, the Company has reached an agreement with Live Current Media Inc. ("LIVC") to extend the Letter of Intent (the "LOI") for an additional 90 day period. Under the LOI the Company will grant LIVC exclusive worldwide distribution rights of the eBalance devices for home based use. For additional information, please refer to the Company's News Release issued on September 14, 2018.
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, and high blood pressure. For moe information about the Company and its technology please visit our website at www.cellmedx.com/investors/overview/. For the Company's newsletter please visit www.cellmedx.com/media/newsletters/.
On behalf of the Board of Directors of Cell MedX Corp.
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, and Annual Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Cell MedX Corp.
For further information please visit: www.cellmedx.com
Toll free: 1.844.238.2692